The authors have characterized a set of cannabinoid CB 2 receptor ligands, including triaryl bis sulfone inverse agonists, in a cell-based receptor/β-arrestin interaction assay (DiscoveRx PathHunter ™ ). The results were compared with results using a competitive ligand binding assay, and with effects on forskolin-stimulated cAMP levels (PerkinElmer LANCE ™ ). The authors show good correlation between the 3 assay systems tested, with the β-arrestin protein complementation assay exhibiting a more robust signal than the cAMP assay for cannabinoid CB 2 agonists. Further assay validation shows that DiscoveRx PathHunter ™ HEK293 CB 2 β-arrestin assay can be carried out from cryopreserved cell suspensions, eliminating variations caused by the need for multiple cell pools during live cell screening campaigns. These results, and the authors' results evaluating a test set of random library compounds, validate the use of ligand-induced interaction between the human cannabinoid CB 2 receptor and β-arrestin as an appropriate and valuable screening platform for compounds specific for the cannabinoid CB 2 receptor. (Journal of Biomolecular Screening 2009:49-58) 
INTRODUCTION
S EVEN TRANSMEMBRANE RECEPTORS remain a significant target class for therapeutic intervention. Functioning as sensors of the extracellular environment, the topology of the ligand binding pocket of these proteins on the external surface of the cellular membrane eliminates the problem of intramembrane sequestration that can hamper development of therapeutics directed toward intracellular targets. They also act as mediators of a diverse set of intracellular effector systems, including the adenyl cyclase-cAMP system, the phosphatidylinositol diphosphateinositol triphosphate system, and calcium ions. These systems mediate an ultimate cellular/tissue event. Compounds that modulate or specifically direct the generation of these intracellular mediators via 7-transmembrane receptors can be of significant therapeutic value.
Our understanding of the opportunities available for controlling the signaling cascade initiated through 7-transmembrane receptors has expanded in recent years. Initially, potential therapeutic entities were considered compounds that either occupied or blocked a ligand binding site-a defined conformation change in the receptor that modulated a single defined signaling cascade was thus altered. We now know that receptors can adopt multiple conformations that can initiate interaction with 1 of several G-protein complexes. 1 Allosteric compounds can be identified that modulate the activity of receptors from regions of the receptor distant from the ligand binding site. 2 Receptors can form heterodimers, in some cases constructing novel ligand binding sites with unique downstream biology. 3 Recent studies have shown that downstream signaling can be mediated via β-arrestin, independent of G-protein complexes altogether. 4 Any of these biologies could be explanations for receptor-specific compounds with complex pharmacology.
Cannabinoids represent a diverse collection of chemotypes that function primarily through the central cannabinoid CB 1 receptor and the peripheral cannabinoid CB 2 receptor. 5 We are particularly interested in a class of triaryl bis sulfone inverse agonists specific for the human cannabinoid CB 2 receptor. 6 We have found that these compounds display a biology not easily explained by classic pharmacology (see Discussion section). Because of these observations, and our desire to assess the value of novel G-protein-coupled receptor (GPCR)-based assay platforms for high-throughput library screening campaigns, we have evaluated a select set of cannabinoid compounds including several triaryl bis sulfones for activation of the cannabinoid CB 2 receptor using the DiscoveRx Pathhunter ™ system. This assay platform uses an enzyme complementation system to detect the interaction between the GPCR C-terminus of interest and β-arrestin. As a first step, we have characterized the potency and efficacy of a set of known cannabinoid ligands, both known standard agonists and a novel set of triaryl bis sulfone inverse agonists, using the DiscoveRx PathHunter ™ HEK293 CB 2 β-arrestin assay. We have compared the pharmacology observed using the PathHunter ™ β-arrestin assay format with that obtained using the PerkinElmer LANCE ™ cAMPbased screening assay. We then used this PathHunter ™ β-arrestin assay system to screen a test library of compounds. The results of this exercise suggest a potential value of this unique cellbased assay platform in identifying and characterizing quality hits for the cannabinoid CB 2 receptor. 
MATERIALS AND METHODS

Materials
Cell culture
The Chinese hamster ovary (CHO) cells expressing recombinant human cannabinoid CB 2 receptor (CHO-hCB 2 cell line) were generated by standard molecular biology techniques using pcDNA3.1 vector (Invitrogen; Carlsbad, CA). Transfected cells were selected and cultivated in Ham's F12 medium (Mediatech catalog number 10-080-CM) containing 10% fetal bovine serum (Gibco catalog number 16140-071), 100 units/ml penicillinstreptomycin (Gibco catalog number 15140-122), and 0.5 mg/ml Geneticin ™ (Gibco catalog number 10131-027). Cells were maintained at less than 70% to 80% confluence (approximately 75,000 cells/cm 2 ). For experiments, spent medium was replaced with medium containing 200 μM 5,6,7,8,4′-pentamethoxyflavone (from 50 mM stock in DMSO), and cells were incubated at 37 °C (5% CO 2 , 95% relative humidity) overnight. Cells were then harvested using trypsin-EDTA (Gibco catalog number 25300-054) and viable cells (assessed using trypan blue dye exclusion) resuspended to 1 × 10 6 cells/ml in medium containing 30 μM 4-(3butoxy-4-methoxybenzyl)imidazolidin-2-one (from 100 mM stock in DMSO).
PathHunter ™ β-arrestin HEK293 CNR2 cell line (catalog number 93-0201C1) and the β-arrestin CHO-K1 GLP1R cell line (catalog number 93-0300C2) were purchased from DiscoveRx Corporation (Fremont, CA). The cell line was engineered to express the β-galactosidase EA fragment fused to β-arrestin and the ProLink complementary peptide fused to the target receptor. The cells were cultivated in DMEM (Invitrogen/BRL catalog number 11960-044) containing 10% fetal bovine serum, 1× penicillin/ streptomycin/glutamate, 200 μg/ml hygromycin, and 600 μg/ml Geneticin ™ . Cells were maintained at less than 70% to 80% confluence (approximately 75,000 cells/cm 2 ).
To test assay robustness of PathHunter ™ β-arrestin HEK293 CNR2 cell line following cell freezing, cells grown to 80% to 90% confluence (80,000 to 120,000 cells/cm 2 ) were resuspended to 2 × 10 7 cells/ml in cell freezing medium (Sigma catalog number C6164-50ML). Aliquots (30 million cells per vial) were pipetted into vials, and the vials placed into Nalgene Cryo 1 °C Freezing Container (catalog number 5100-001) containing 250 ml of 100% ethanol. After treatment at -80 °C overnight the vials were transferred into a liquid nitrogen storage system. For assay, frozen cell suspension was thawed in a 37 °C water bath, and the cells washed in Dulbecco's phosphate-buffered saline (minus calcium chloride and magnesium chloride). The resulting cell pellet was resuspended in desired assay buffer as required.
cAMP assay-LANCE ™ ™ (PerkinElmer)
LANCE ™ cAMP competitive immunoassay (catalog number AD0264; PerkinElmer Inc., Boston, MA) was performed as described by the manufacturer. Assay plates were prepared containing 5 μl of test compound in buffer containing 10 μM (final concentration) forskolin. Tangeretin-treated cells (5000 cells in 5 μl) were added in buffer containing 30 μM (final concentration) RO20-1724 and LANCE ™ "Alexa Fluor anti-cAMP antibody" using a MultiDrop Microplate Reagent Dispenser (Thermo Electron Corporation, Waltham, MA). After incubation for 45 min at room temperature, LANCE ™ "detection buffer" (10 μl) was added and the reaction allowed to incubate for 60 min at room temperature. The plates were then quantitated using an EnVision multilabel plate reader (Perkin Elmer Corp.).
β β-Arrestin translocation assay-PathHunter™ ™ (DiscoveRx)
The PathHunter ™ protein complementation assay (DiscoveRx Corporation) was performed according to the manufacturer's protocol. Assay plates (Thermo Fisher Scientific number 4342 ScreenMates 384-well U-bottom white polypropylene microplates) were prepared containing 5000 cells in 25 μl. After incubation at 37 °C (5% CO 2 , 95% relative humidity) overnight, 2.5 μl of test compound was added (1% final DMSO concentration) and the incubation continued at 37 °C for 90 min. Detection agent (12 μl) was then added and the incubation continued at room temperature for 60 min. Plates were then analyzed for a chemiluminescent signal using a LeadSeeker high-throughput imaging system (GE Healthcare Life Sciences, Piscataway, NJ).
Membrane binding assays
Membrane binding assays were performed as previously described. 7 Compound dilutions were carried out in triplicate in binding buffer (25 mM Tris, 3 mM MgCl 2 , 1 mM EDTA, and 0.1% (wt/vol) BSA (Factor V), pH 7.4) containing 10% DMSO and 0.4% methyl cellulose (Sigma, catalog number M-6385). Aliquots were added in 1/10 volume to [ 3 H]CP55,940 (0.4 nM, specific activity = 180 Ci/mmol; New England Nuclear, Boston, MA) and cell membranes (6-8 µg/point; PerkinElmer catalog number RBXCB2M) in binding buffer. After incubation at room temperature for 2 h, the reaction was terminated by rapid filtration through microfiltration plates coated with 0.5% polyethylenimine (UniFilter GF/C filter plate; Packard, Meriden, CT). Bound radioactivity was analyzed for K i using nonlinear regression analysis (Prism 2.0b, GraphPad, San Diego, CA), with the K d values for [ 3 H]CP55,940 determined from saturation experiments.
Data analysis
Data from nonscreening experiments were analyzed using Prism 2.0b (GraphPad, San Diego, CA). Data from screening experiments were analyzed using an Oracle-based proprietary data management system developed by Schering-Plough Research Institute, New Lead Discovery. Integration of data with a specific compound is managed by the system through tracking of compound transfers to and from bar coded plates. Robustness of assay data is determined by calculation of Z′ factor.
RESULTS
Our initial efforts to identify cannabinoid CB 2 receptorspecific compounds utilized a radioligand-based competitive binding assay with a recombinant membrane preparation. This system, insensitive to the pharmacology of potential hit compounds, resulted in the identification of the triaryl bis sulfone class of cannabinoid CB 2 receptor-specific inverse agonist. 7 Efforts to specifically identify cannabinoid CB 2 receptorspecific agonists utilized a recombinant cell-based cAMP competitive immunoassay, the LANCE ™ cAMP Detection Kit from PerkinElmer. To achieve the robustness required for library screening, the recombinant cell biosensor was treated with the kinase inhibitor tangeretin, 8 which improved the signal-to-background ratio achieved using this platform. In an effort to identify additional screening methods to interrogate GPCR targets for ligands with a defined pharmacology, we evaluated the ability of the DiscoveRx PathHunter ™ β-arrestin assay platform to identify pharmacologically defined compounds from a complex compound library. This system utilizes enzyme complementation to target the interaction between the GPCR of choice (in this example, the human cannabinoid CB 2 receptor) and β-arrestin 2, a biology involved in receptor desensitization and the first step of a potential novel signaling pathway. 4 We sought to confirm the ability of this system to accurately identify standard cannabinoid ligands, and then to probe whether the system may identify additional novel compounds involved in β-arrestin-dependent signaling.
We first sought to confirm the ability of the receptor/βarrestin system to accurately identify the pharmacology of known cannabinoid ligands. For this evaluation, equivalent cell aliquots (5000 cells per well) of either CHO-hCB 2 cells (pretreated with tangeretin for forskolin-stimulated cAMP measurements) or PathHunter ™ HEK293 CNR2 β-arrestin cells were treated with selected cannabinoid test compounds as described in Materials and Methods. Cell lines were optimized for each assay platform to ensure appropriate signal pathway coupling. After incubation, designated detection reagent was added, and incubation continued at room temperature for 60 min. The plates were then quantitated using an EnVision multilabel plate reader (PerkinElmer Inc.) for LANCE™ cAMP assay or using LeadSeeker (GE Healthcare Life Sciences) for measuring enzyme complementation. Figure 1 shows that both assay systems successfully detected both cannabinoid agonists and inverse agonists. Panel 1A shows that indole-based agonists (JWH015 and WIN55,212-2) and the dimethylheptyl side chain-containing bicyclic CP55,940 all generate a robust response to forskolin-stimulated cAMP levels using LANCE ™ . JWH015 showed a marginal increase in efficacy in these experiments. The indole-based partial agonist GW405833 and the butane sulfonate-based partial agonist BAY59-3074 both show a diminished effect in the assay, expected for partial agonists. Panel B shows that this same assay successfully detected the triaryl bis sulfone cannabinoid CB 2 receptor inverse agonists. Finally, we extended this analysis using the HEK293-based PathHunter ™ β-arrestin CNR2 assay system (DiscoveRx, Inc., catalog number 93-0201C1). Figure 1C shows that both CP55,940 and JWH015 function as full agonists, with an improved signal to background relative to the LANCE ™ cAMP Characterizing Cannabinoid CB2 Receptor Ligands system. WIN55,212-2 efficacy appears slightly diminished relative to CP55,940 and JWH015. Panel D shows the pharmacology of the triaryl bis sulfone cannabinoid CB 2 receptor inverse agonists. We then used these data to compare the potency and efficacy of the selected cannabinoid agonists/partial agonists/ inverse agonists obtained using the 2 cell-based assay formats with that obtained using competitive binding of [ 3 H]CP55,940 to recombinant membranes engineered to contain human cannabinoid CB 2 receptor (PerkinElmer catalog number RBXCB2M). Table 1 shows an overall good correlation between the IC 50 values obtained using all 3 methodologies. The data generated using a preparation of GW405883 showed the greatest deviation from reported values, reflecting the low signal/background obtained with this compound. Comparing binding data with the cellbased activity data, the potency of several of the cannabinoid CB 2 inverse agonists showed minor potency shifts relative to that seen with the forskolin-stimulated cAMP assay platform. With this minor question, we conclude that, for selected cannabinoid CB 2 receptor compounds, the pharmacology observed using a standard cAMP second messenger assay was matched using this novel β-arrestin interaction assay.
Having concluded that the PathHunter ™ β-arrestin CNR2 assay system is capable of identifying these standard cannabinoid compounds, we sought to compare the robustness of the cell-based β-arrestin system with that of the cell-based cAMP system in a 384-well assay format. In Figure 2A , forskolinstimulated CHO-hCB 2 cells (5000 cells per well) pretreated with tangeretin were incubated with and without saturating concentrations of CP55,940. These data correspond to a calculated Z′ factor of 0.62 (median Z′ for screening campaign = 0.53; D. McGuinness [2006] , unpublished data). We compared these results with those obtained using the PathHunter ™ βarrestin CNR2 assay system. In Figure 2B , saturating concentration of CP55,940 was added to 96 wells of a 384-well plate, and the resulting signal compared with that present in wells containing DMSO. The panel shows that the β-arrestin assay achieved a Z′ factor of 0.7, comparable with the values achieved using forskolin-stimulated cAMP.
As part of our assay validation criteria, and to investigate the flexibility of the receptor/β-arrestin assay system, we carried out several ranging studies on the sensitivity and robustness of the assay. We first tested the sensitivity of the assay to increasing concentrations of DMSO using both freshly prepared and frozen cell preparations. For these experiments, aliquots of PathHunter ™ β-arrestin HEK293 CNR2 cells grown to 80% to 90% confluence were cooled at -1 °C/min to -80 °C in a 100% ethanol bath (Nalgene Cryo 1 °C Freezing Container). Frozen cells were quick-thawed, washed, then resuspended for assay. Figure 3 shows that the assay is insensitive to increasing concentrations of DMSO up to 2% using both preparations. This is sufficient for most screening applications. We then confirmed the ability of the β-arrestin assay system to be carried out in frozen cells, an approach increasingly being used to simplify scheduling and to improve cell-based assay robustness, 9 by testing the pharmacology of selected cannabinoid compounds. Figure 4 shows that both fresh and frozen cell preparations show comparable signal/background and comparable pharmacology for the 3 cannabinoid agonists tested. We next tested the number of cells required for a robust signal. As expected, Figure 5 shows that decreasing cell number decreases the detected signal, with 1500 cells per well exhibiting a signal-tobackground ratio of approximately 2-fold.
Finally, we compared the ability of the PathHunter ™ β-arrestin CNR2 assay system to identify novel compounds from a complex compound library. We designed a small-scale screening exercise using the LOPAC ™ library of pharmacologically active compounds (Sigma-Aldrich). In this validation step, 1280 "pharmacologically active" compounds (assayed at 2.5 μM for each compound, a maximal amount tolerated in mixture screening) were tested for the ability to modulate cannabinoid CB 2 receptor activity using either forskolin-stimulated CHO-hCB 2 cells to measure changes in cAMP or the β-arrestin CNR2 cells to measure ligand-induced receptor/β-arrestin interaction. The assay was carried out as orthogonal compound mixtures (8 compounds per well, present twice on each plate). For assays that tolerate mixture screening, this approach 1) condenses screening library, permitting more campaigns per year, 2) simplifies assay development by permitting screening in 384-well formats, and 3) minimizes false positives by screening all compounds twice. Seven compounds were identified in the LOPAC ™ screening experiment using forskolin-stimulated cAMP in CHO-hCB 2 cells ( Table 2) . Two compounds, JWH015 and δ2 opioid receptor antagonist naltriben methane sulfonate, gave a more robust signal in the β-arrestin assay (note that the apparent decreased efficacy of JWH015 in modulating forskolin-stimulated cAMP was mirrored in the dose-response experiments presented in Figure 1 -WIN55,212-2 did not reproduce this apparent decreased efficacy). Naltriben methane sulfonate modulated the receptor/β-arrestin assay with an EC 50 = 0.64 μM (Fig. 6) . One compound, the glutamate receptor antagonist NBQX disodium, was uniquely identified by the forskolin-stimulated cAMP screening assay. Importantly, 5 compounds appeared unique to the β-arrestin CNR2 screening assay ( A and B) Tangeretin-treated CHO-hCB 2 cells were added to wells containing diluted test compound in forskolin, RO20-1724, and LANCE ™ "Alexa Fluor anti-cAMP antibody." After incubation, detection reagent was added and plates as described in Materials and Methods. (C and D) Diluted test compound was added to wells preloaded with PathHunter ™ β-arrestin HEK293 CNR2 cells. After incubation, detection reagent was added and plates as described in Materials and Methods. JWH015 ( ); WIN55,212-2 (Δ); CP55,940 ( ); GW405833 ( ); BAY59-3074 ( ); Sch.414428 ( ); Sch.225336 ( ); Sch.356036 ( ); Sch.414319 ( ). Data expressed as mean ± standard error of 5 determinations. CHO-hCB 2 , Chinese hamster ovary cells expressing recombinant human cannabinoid CB 2 receptor. hits, with EC 50 values of 0.055 μM and >10 μM, respectively (Fig. 6B) . This activity appears specific for the cannabinoid CB 2 receptor system and not the result of the assay system itselffenofibrate and REV 5901 showed no agonist activity in an unrelated receptor/β-arrestin assay system specific for the GLP1 receptor (Fig. 6C) .
DISCUSSION
As a class, the biology of cannabinoids display a biology not easily explained by classic pharmacology. For example, cannabinoid agonists have been shown to induce chemotaxis 10 via a mechanism that may target nondirected (chemokinesis) cell movement. 11 This is evidenced by the extension of nondirected pseudopods from cells treated with 2-arachidonoylglycerol and with JWH015. 12 Cannabinoids have also been shown to inhibit chemotaxis. 13, 14 Cannabinoid inverse agonists, both synthetic 6 and natural, 15 can block both cannabinoid agonist-mediated chemotaxis and chemokine-induced chemotaxis in vitro and in vivo. 15, 16 Cannabinoid CB 2 receptor-specific agonists exhibit potent effects on modulating pain, 17 although receptor-specific inverse agonists do not induce a detected hypoalgesia. 16 Cannabinoid agonists have been shown to alleviate the symptoms of experimental autoimmune encephalomyelitis (EAE; Maresz et al. 18 ) although we have data showing that cannabinoid CB 2 receptor-specific inverse agonists can alleviate EAE symptoms. 16, 19 Ofek and colleagues showed that cannabinoid CB 2 receptor-deficient mice exhibit an age-related bone loss phenotype. 20 These investigators also show that a cannabinoid CB 2 receptor agonist attenuates OVX-induced femoral bone loss. These results, coupled with the clinical observations that the cannabinoid CB 2 receptor is associated with osteoporosis in human populations 21 suggest that cannabinoid agonists play a role in the maintenance of bone mass via CB 2 . However, antagonists of the cannabinoid CB 1 and CB 2 receptors prevented ovariectomy-induced bone loss in vivo and caused osteoclast inhibition in vitro. 22 We have demonstrated that a cannabinoid CB 2 receptor inverse agonist can block bone destruction in an antigen-induced model of arthritis. 23 There are many explanations for this complex pharmacology. Variations in cannabinoid compound biology/pharmacology can be attributed to a primary role of some alternative receptor systems, including GPR55 or the TRPV1 (vanilloid) receptor. 24 The biology could be the result of activation of different cell types, and that this activation results in unique biology. Agonistselective G-protein signaling has been demonstrated for the cannabinoid CB 1 receptor. 25 Ligands can also signal via the β-arrestin-based system, with some ligands acting exclusively through this G-protein-independent pathway. 4 We were interested in interrogating our cannabinoid CB 2 receptor inverse agonists using a β-arrestin-based screening platform because of data showing an association of β-arrestin 2 in the control of cellular chemotaxis. 26 In addition to a role in chemokine receptor downregulation, several investigators have identified β-arrestin-dependent mechanisms involving actin bundling and cytoskeletal reorganization. 27, 28 It is interesting that cannabinoid CB 2 receptor-specific Sch.414319 modulates (by phosphorylation) the activity of the actin bundling protein L-plastin, 19 a protein involved in cytoskeletal organization. Mice lacking β−arrestin 2 expressed diminished airway responsiveness and diminished cellular influx into lungs in an ovalbumin-induced model of asthma. 29 CNR2 cells were quick frozen as described. The frozen cell suspension was quick thawed and remaining receptor β-arrestin interaction activity measured versus freshly prepared nonfrozen cells as described. JWH015 ( ); WIN55,212-2 (Δ); CP55,940 ( ). Data expressed as mean ± standard error of 5 determinations. In this set of experiments, we compared the potency of a selection of cannabinoid test compounds in 3 assay systems, and carried out quantitative pharmacology experiments in 2 systems. We demonstrate fairly good correlation between the 3 assay systems. We also show that the β-arrestin system can be used to identify 6 compounds (including 3 cannabinoid ligands) previously identified from the LOPAC validation library using the cAMP-based LANCE ™ screening platform. Of particular interest, screening this validation library identified 2 compounds, the PPARα receptor agonist fenofibrate and the leukotriene D4 receptor antagonist REV 5901, uniquely associated with the cannabinoid CB 2 receptor/β-arrestin assay. Screening the LOPAC library in the same dose range versus several other 7-transmembrane receptors (including the Gs-linked β 2adrenoceptor, the Gi-linked somatostatin 2 receptor, and the Gslinked melanocortin-4 receptor) failed to identify these compounds as hits ((K. Olson [2008] , personal communication). These compounds showed no activity when evaluated in the GLP1 receptor/β-arrestin complementation assay ( Fig. 6C) , suggesting a unique linkage to the cannabinoid receptor. This is of particular interest when considering our results with the PPARα receptor agonist fenofibrate. Experimental evidence has linked cannabinoids and PPAR receptors, and cannabinoid derivatives have been shown to interact with the PPAR receptors. 30 Again, the significance of fenofibrate to cannabinoid biology must await further experimentation.
In conclusion, we have demonstrated that the DiscoveRx PathHunter ™ β-arrestin assay is a robust, sensitive assay well suited for high-throughput screening. Specifically, the assay gives a particularly robust response for signaling via the cannabinoid CB 2 receptor. Characterization of selected cannabinoid compounds showed good correlation in efficacy of the 3 assays tested. No unique pharmacology could be ascertained upon characterization of the cannabinoid CB 2 receptor-specific triaryl bis sulfone inverse agonists with this system. Assay validation using the LOPAC compound library showed good correlation with previous analyses using the cAMP-based LANCE ™ assay platform, and identified several unique compounds that may be specific to the cannabinoid CB 2 receptor/ β-arrestin system. Further experiments are needed to determine whether these novel compounds will help characterize the details of the full range of activities mediated by the cannabinoid CB 2 receptor class of 7-transmembrane receptors.
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